Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

JAK3 Variant, Immune Signatures, DNA Methylation, and Social Determinants Linked to Survival Racial Disparities in Head and Neck Cancer Patients.

Guerrero-Preston R, Lawson F, Rodriguez-Torres S, Noordhuis MG, Pirini F, Manuel L, Valle BL, Hadar T, Rivera B, Folawiyo O, Baez A, Marchionni L, Koch WM, Westra WH, Kim YJ, Eshleman JR, Sidransky D.

Cancer Prev Res (Phila). 2019 Apr;12(4):255-270. doi: 10.1158/1940-6207.CAPR-17-0356. Epub 2019 Feb 18.

PMID:
30777857
2.

Integrated transcriptomic and epigenomic analysis of ovarian cancer reveals epigenetically silenced GULP1.

Maldonado L, Brait M, Izumchenko E, Begum S, Chatterjee A, Sen T, Loyo M, Barbosa A, Poeta ML, Makarev E, Zhavoronkov A, Fazio VM, Angioli R, Rabitti C, Ongenaert M, Van Criekinge W, Noordhuis MG, de Graeff P, Wisman GBA, van der Zee AGJ, Hoque MO.

Cancer Lett. 2018 Oct 1;433:242-251. doi: 10.1016/j.canlet.2018.06.030. Epub 2018 Jun 28.

PMID:
29964205
3.

Viable tumor in salvage neck dissections in head and neck cancer: Relation with initial treatment, change of lymph node size and human papillomavirus.

van den Bovenkamp K, Dorgelo B, Noordhuis MG, van der Laan BFAM, van der Vegt B, Bijl HP, Roodenburg JL, van Dijk BAC, Oosting SF, Schuuring EMD, Langendijk JA, Halmos GB, Plaat BEC.

Oral Oncol. 2018 Feb;77:131-136. doi: 10.1016/j.oraloncology.2017.12.017. Epub 2018 Jan 8.

PMID:
29362119
4.

Clinical outcome of salvage neck dissections in head and neck cancer in relation to initial treatment, extent of surgery and patient factors.

van den Bovenkamp K, Noordhuis MG, Oosting SF, van der Laan BFAM, Roodenburg JL, Bijl HP, Halmos GB, Plaat BEC.

Clin Otolaryngol. 2017 Jun;42(3):693-700. doi: 10.1111/coa.12818. Epub 2017 Jan 24.

PMID:
28032952
5.

16S rRNA amplicon sequencing identifies microbiota associated with oral cancer, human papilloma virus infection and surgical treatment.

Guerrero-Preston R, Godoy-Vitorino F, Jedlicka A, Rodríguez-Hilario A, González H, Bondy J, Lawson F, Folawiyo O, Michailidi C, Dziedzic A, Thangavel R, Hadar T, Noordhuis MG, Westra W, Koch W, Sidransky D.

Oncotarget. 2016 Aug 9;7(32):51320-51334. doi: 10.18632/oncotarget.9710.

6.

Key tumor suppressor genes inactivated by "greater promoter" methylation and somatic mutations in head and neck cancer.

Guerrero-Preston R, Michailidi C, Marchionni L, Pickering CR, Frederick MJ, Myers JN, Yegnasubramanian S, Hadar T, Noordhuis MG, Zizkova V, Fertig E, Agrawal N, Westra W, Koch W, Califano J, Velculescu VE, Sidransky D.

Epigenetics. 2014 Jul;9(7):1031-46. doi: 10.4161/epi.29025. Epub 2014 May 1.

7.

Genome-wide methylation profiling reveals Zinc finger protein 516 (ZNF516) and FK-506-binding protein 6 (FKBP6) promoters frequently methylated in cervical neoplasia, associated with HPV status and ethnicity in a Chilean population.

Brebi P, Maldonado L, Noordhuis MG, Ili C, Leal P, Garcia P, Brait M, Ribas J, Michailidi C, Perez J, Soudry E, Tapia O, Guzman P, Muñoz S, Van Neste L, Van Criekinge W, Irizarry R, Sidransky D, Roa JC, Guerrero-Preston R.

Epigenetics. 2014 Feb;9(2):308-17. doi: 10.4161/epi.27120. Epub 2013 Nov 15.

8.

Association of promoter methylation of VGF and PGP9.5 with ovarian cancer progression.

Brait M, Maldonado L, Noordhuis MG, Begum S, Loyo M, Poeta ML, Barbosa A, Fazio VM, Angioli R, Rabitti C, Marchionni L, de Graeff P, van der Zee AG, Wisman GB, Sidransky D, Hoque MO.

PLoS One. 2013 Sep 27;8(9):e70878. doi: 10.1371/journal.pone.0070878. eCollection 2013. Erratum in: PLoS One. 2013;8(10). doi:10.1371/annotation/ccd51e37-fdf3-466e-b79f-2c390df9ab28. PLoS One. 2013;8(10). doi:10.1371/annotation/5d2e13d4-cb4e-44b1-a836-dff9b4144b5b. Noordhuis, Maartje [corrected to Noordhuis, Maartje G].

9.

Genome-wide methylation profiling and the PI3K-AKT pathway analysis associated with smoking in urothelial cell carcinoma.

Brait M, Munari E, LeBron C, Noordhuis MG, Begum S, Michailidi C, Gonzalez-Roibon N, Maldonado L, Sen T, Guerrero-Preston R, Cope L, Parrella P, Fazio VM, Ha PK, Netto GJ, Sidransky D, Hoque MO.

Cell Cycle. 2013 Apr 1;12(7):1058-70. doi: 10.4161/cc.24050. Epub 2013 Feb 22.

10.

OGDHL is a modifier of AKT-dependent signaling and NF-κB function.

Sen T, Sen N, Noordhuis MG, Ravi R, Wu TC, Ha PK, Sidransky D, Hoque MO.

PLoS One. 2012;7(11):e48770. doi: 10.1371/journal.pone.0048770. Epub 2012 Nov 12.

11.

The role of ATM and 53BP1 as predictive markers in cervical cancer.

Roossink F, Wieringa HW, Noordhuis MG, ten Hoor KA, Kok M, Slagter-Menkema L, Hollema H, de Bock GH, Pras E, de Vries EG, de Jong S, van der Zee AG, Schuuring E, Wisman GB, van Vugt MA.

Int J Cancer. 2012 Nov 1;131(9):2056-66. doi: 10.1002/ijc.27488. Epub 2012 Mar 29.

12.

Clinical and public health research using methylated DNA immunoprecipitation (MeDIP): a comparison of commercially available kits to examine differential DNA methylation across the genome.

Brebi-Mieville P, Ili-Gangas C, Leal-Rojas P, Noordhuis MG, Soudry E, Perez J, Roa JC, Sidransky D, Guerrero-Preston R.

Epigenetics. 2012 Jan 1;7(1):106-12. doi: 10.4161/epi.7.1.18647. Epub 2012 Jan 1.

13.

Involvement of the TGF-beta and beta-catenin pathways in pelvic lymph node metastasis in early-stage cervical cancer.

Noordhuis MG, Fehrmann RS, Wisman GB, Nijhuis ER, van Zanden JJ, Moerland PD, Ver Loren van Themaat E, Volders HH, Kok M, ten Hoor KA, Hollema H, de Vries EG, de Bock GH, van der Zee AG, Schuuring E.

Clin Cancer Res. 2011 Mar 15;17(6):1317-30. doi: 10.1158/1078-0432.CCR-10-2320. Epub 2011 Mar 8.

14.

Prognostic cell biological markers in cervical cancer patients primarily treated with (chemo)radiation: a systematic review.

Noordhuis MG, Eijsink JJ, Roossink F, de Graeff P, Pras E, Schuuring E, Wisman GB, de Bock GH, van der Zee AG.

Int J Radiat Oncol Biol Phys. 2011 Feb 1;79(2):325-34. doi: 10.1016/j.ijrobp.2010.09.043. Review.

PMID:
21195874
15.

The epidermal growth factor receptor pathway in relation to pelvic lymph node metastasis and survival in early-stage cervical cancer.

Eijsink JJ, Noordhuis MG, ten Hoor KA, Kok M, Hollema H, de Bock GH, Nijman HW, Schuuring E, Wisman GB, van der Zee AG.

Hum Pathol. 2010 Dec;41(12):1735-41. doi: 10.1016/j.humpath.2010.04.017.

PMID:
21078436
16.

Expression of epidermal growth factor receptor (EGFR) and activated EGFR predict poor response to (chemo)radiation and survival in cervical cancer.

Noordhuis MG, Eijsink JJ, Ten Hoor KA, Roossink F, Hollema H, Arts HJ, Pras E, Maduro JH, Reyners AK, de Bock GH, Wisman GB, Schuuring E, van der Zee AG.

Clin Cancer Res. 2009 Dec 1;15(23):7389-97. doi: 10.1158/1078-0432.CCR-09-1149. Epub 2009 Nov 17.

17.

The prognostic value of TRAIL and its death receptors in cervical cancer.

Maduro JH, Noordhuis MG, ten Hoor KA, Pras E, Arts HJ, Eijsink JJ, Hollema H, Mom CH, de Jong S, de Vries EG, de Bock GH, van der Zee AG.

Int J Radiat Oncol Biol Phys. 2009 Sep 1;75(1):203-11. doi: 10.1016/j.ijrobp.2009.03.071.

PMID:
19695437

Supplemental Content

Loading ...
Support Center